<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In previous studies, we demonstrated an over-expression of the dominant-negative isoform of the transcription factor Ikaros, Ik-6, in patients with B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, including <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> of <z:hpo ids='HP_0011010'>chronic</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> and <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>To investigate the consequence of over-expression of Ik-6 in B cells, we constructed Ik-6 transfectants of the FDH-1 and Ramos cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>FDH-1, which was established from a patient with early pre-B <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>, undergoes <z:mpath ids='MPATH_3'>apoptosis</z:mpath> with <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> treatment, whereas Ramos undergoes <z:mpath ids='MPATH_3'>apoptosis</z:mpath> following anti-IgM antibody treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Compared with the <z:mp ids='MP_0002169'>wild type</z:mp>, the over-expression of Ik-6 rendered the FDH-1 and Ramos transfectants resistant to <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>-induced and anti-IgM-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> respectively </plain></SENT>
<SENT sid="4" pm="."><plain>An immunoblotting study demonstrated bcl-2 upregulation in anti-IgM-induced Ramos Ik-6 transfectants, but not in FDH-1 Ik-6 transfectants </plain></SENT>
<SENT sid="5" pm="."><plain>Further investigations of the mechanism of leukaemogenesis associated with the over-expression of Ik-6 are warranted </plain></SENT>
</text></document>